Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Patients with melanoma brain metastases have a poor prognosis and historically have been excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity to evaluate the feasibility of ipilimumab (3 mg/kg every 3 weeks for four doses) in patients with stage 3 (unresectable) o...

Full description

Saved in:
Bibliographic Details
Main Authors: Queirolo, Paola, Spagnolo, Francesco, Ascierto, Paolo Antonio, Simeone, Ester, Marchetti, Paolo, Scoppola, Alessandro, Del Vecchio, Michele, Di Guardo, Lorenza, Maio, Michele, Di Giacomo, Anna Maria, Antonuzzo, Andrea, Cognetti, Francesco, Ferraresi, Virginia, Ridolfi, Laura, Guidoboni, Massimo, Guida, Michele, Pigozzo, Jacopo, Chiarion Sileni, Vanna
Format: Artigo
Language:Inglês
Published: Springer US 2014
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4023079/
https://ncbi.nlm.nih.gov/pubmed/24532241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1400-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items